创业慧康科技股份有限公司 1、本次股东大会无新增、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开； 证券代码：300451 证券简称：创业慧康 公告编号：2024-039 2024年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： （2）网络投票日期和时间：2024 年 10 月 21 日。其中，通过深圳证券交易 所交易系统进行网络投票的具体时间为：2024年10月21日9:15-9:25、9:30-11:30， 13:00-15:00。通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 10 月 21 日 9:15 至 2024 年 10 月 21 日 15:00 的任意时间。 2、召开地点：杭州市滨江区浦沿街道坚塔街 708 号创业慧康大厦三楼会议。 3、召开方式：现场投票和网络投票相结合的方式。 4、为尊重中小投资者利益，提高中小投资者对本次股东大会决议事项的参 与度，本次股东大会对审议影响中小投资者利益的重大事项进行单独计票。中小 ...

本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，创业慧康科技股份有限公司(以下简称"公司")董事会收到公司财务 总监陈锦剑先生提交的书面辞职报告，陈锦剑先生因个人原因申请辞去公司财务 总监职务，辞去上述相关职务后，陈锦剑先生将不在公司及子公司担任任何职务。 陈锦剑先生确认与公司董事会并无不同意见，亦无任何与辞职有关的事项需 知会公司股东及债权人。根据《公司法》《公司章程》以及相关法律法规的规定， 陈锦剑先生的辞职自申请送达董事会之日起生效。陈锦剑先生的辞职不会影响公 司相关工作的正常开展，不会对公司生产经营产生不利影响。 截至本公告披露日，陈锦剑先生未持有本公司股份，其不存在应当履行而未 履行的承诺，其辞职后将继续按照《上市公司董事、监事和高级管理人员所持本 公司股份及其变动管理规则》等相关法律、法规、规范性文件的要求对其股份进 行管理。 证券代码：300451 证券简称：创业慧康 公告编号：2024-037 创业慧康科技股份有限公司 关于公司财务总监离职 暨董事会秘书代行财务总监职责的公告 陈锦剑先生在任职期间，认真履职、勤勉尽责，为公司财务规范运作与健康 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-036 创业慧康科技股份有限公司 关于公司非独立董事辞职的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）董事会于近日收到公司董 事KWOK WAI ANDY HO（何国伟）先生、叶江先生提交的书面辞职报告。KWOK WAI ANDY HO（何国伟）先生、叶江先生因个人工作原因申请辞去公司非独立 董事职务。同时，KWOK WAI ANDY HO（何国伟）先生申请辞去第八届董事会 战略与ESG委员会委员职务，叶江先生申请辞去第八届董事会提名委员会委员职 务。辞去上述职务后，KWOK WAI ANDY HO（何国伟）先生、叶江先生不再担 任公司任何职务。 根据《公司法》《公司章程》的相关规定，KWOK WAI ANDY HO（何国伟）、 叶江先生的辞职未导致公司董事会成员低于法定最低人数，不会影响公司董事会 正常运作和公司正常生产经营，辞职报告自送达董事会时生效。 特此公告。 创业慧康科技股份有限公司 董事会 2024 年 10 月 1 日 KWOK WA ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-038 2024 年第一次临时股东大会会议的召集、召开符合有关法律、行政法规、部 门规章、规范性文件和公司章程的相关规定。 4、会议召开时间： 创业慧康科技股份有限公司 关于召开2024年第一次临时股东大会的通知 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2024 年 9 月 30 日召开 了第八届董事会第九次会议，会议决定于 2024 年 10 月 21 日召开 2024 年第一次 临时股东大会。本次股东大会采用现场投票、网络投票相结合的方式进行，现将 本次会议的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年第一次临时股东大会 2、股东大会的召集人：公司第八届董事会 3、会议召开的合法、合规性 （1）截至 2024 年 10 月 15 日（星期二）下午 15：00 深圳证券交易所收市 时，在中国证券登记结算有限责任公司深圳分公司登记在册的公司全体普通股股 东均有权按照本通知公布的方式出席本次股东大会，并可以以书面形式委 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-035 创业慧康科技股份有限公司 第八届董事会第九次会议决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届董事 会第九次会议的通知于 2024 年 9 月 26 日以邮件、传真等方式向各位董事发出， 并于 2024 年 9 月 30 日在公司三楼会议室以现场结合通讯的方式召开。会议应到 董事 9 名，实到董事 9 名，公司部分监事、高级管理人员列席了会议。会议的召 开及表决符合《中华人民共和国公司法》《创业慧康科技股份有限公司章程》等 有关规定。 此次会议由董事长张吕峥先生主持，参会董事认真审议后，依照有关规定通 过以下几项决议： 一、审议通过了《关于提名第八届董事会非独立董事候选人的议案》 公司第八届董事会董事 KWOK WAI ANDY HO（何国伟）先生和叶江先生 因个人原因申请辞去董事职务，相应需补选非独立董事人员。根据《公司法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 ...

[Table_MainInfo] 公司研究/信息服务/软件 证券研究报告 创业慧康（300451）公司跟踪报告 2024 年 09 月 19 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-----------------------------------------------------------------|-----------| | 股票数据 | | | 09 [ Table_StockInfo 月 18 日收盘价（元） ] | 3.23 | | 52 周股价波动（元） | 3.06-7.96 | | 总股本 / 流通 A 股（百万股） | 1549/1527 | | 总市值 / 流通市值（百万元） | 5004/4931 | | 相关研究 | | | [Table_ReportInfo] 《 Hi-HIS 推广新阶段，盈利能力有望快速修 | | | 复》 2024.04.15 | | 市场表现 [Table_QuoteInfo] -51.67% -36.67% -21.67% -6.67% 8.33% 2023/9 2023/12 2024/ ...

证券研究报告 非金融公司|公司点评|创业慧康（300451） HI-HIS 系统助力，AI 打造智慧医疗生 态 请务必阅读报告末页的重要声明 glzqdatemark1 2024年09月02日 证券研究报告 |报告要点 创业慧康发布 2024 年半年度报告，2024 年上半年公司实现营收 7.27 亿元，同比增长 3.17%； 归母净利润 0.27 亿元，同比增长 14.03%；扣非归母净利润 0.25 亿元，同比增长 36.77%；毛 利率为 54.21%，同比增长 2.32pct。2024 年第二季度公司实现营收 3.51 亿元，同比减少 1.32%； 归母净利润 0.15 亿元，同比增长 10.22%；扣非归母净利润 0.16 亿元，同比增长 28.98%；毛 利率为 56.98%，同比增加 5.11pct。 |分析师及联系人 黄楷 陈安宇 SAC：S0590522090001 SAC：S0590523080004 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年09月02日 创业慧康(300451) HI-HIS 系统助力，AI 打造智慧医疗生态 ...

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a 6-month target price of 4.09 CNY, compared to the current stock price of 3.33 CNY [6][10]. Core Insights - The company achieved a revenue of 727 million CNY in the first half of 2024, representing a year-on-year growth of 3.17%. The medical industry segment contributed 693 million CNY, growing by 8.61% [3][4]. - The net profit attributable to shareholders reached 27.376 million CNY, up 14.03% year-on-year, while the net profit excluding non-recurring items was 25.217 million CNY, marking a significant increase of 36.77% [3][4]. - The company has seen a substantial increase in large orders, with orders exceeding 30 million CNY growing by 110.83% compared to the same period last year, enhancing its competitive advantage and market share [4][5]. Financial Performance - The company's gross margin improved to 54.21%, an increase of 2.33 percentage points year-on-year. The revenue breakdown shows software sales at 287 million CNY (YoY +0.02%), technical services at 293 million CNY (YoY +9%), and system integration at 79.67 million CNY (YoY +9.53%) [4]. - The projected revenues for 2024, 2025, and 2026 are 1.857 billion CNY, 2.125 billion CNY, and 2.416 billion CNY, respectively, with net profits expected to be 181 million CNY, 266 million CNY, and 337 million CNY [10][12]. Strategic Developments - The company is actively expanding its collaboration with Philips, with over 50 ongoing projects for its HI-HIS product, primarily in tertiary hospitals. The product has already been implemented in 12 hospitals [5]. - The company has successfully launched the "Jiangxi Province Grassroots AI-Assisted Smart Medical System," which is the first of its kind in the country, covering extensive healthcare functionalities across the province [5].

Financial Performance - Revenue for the reporting period was RMB 726.74 million, a year-on-year increase of 3.17%[10] - Net profit attributable to shareholders of the listed company was RMB 27.38 million, a year-on-year increase of 14.03%[10] - Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 25.22 million, a year-on-year increase of 36.77%[10] - Operating cash flow was negative RMB 192.45 million, a year-on-year decrease of 12.33%[10] - Total assets at the end of the reporting period were RMB 5.72 billion, a year-on-year decrease of 1.28%[10] - Shareholders' equity attributable to the listed company at the end of the reporting period was RMB 4.63 billion, a year-on-year increase of 0.58%[10] - Basic earnings per share were RMB 0.02, unchanged from the same period last year[10] - Weighted average return on equity was 0.59%, an increase of 0.07 percentage points year-on-year[10] - Revenue for the reporting period was 727 million yuan, a year-on-year increase of 3.17%, with medical industry revenue reaching 693 million yuan, up 8.61% year-on-year[27] - Orders exceeding 30 million yuan increased by 110.83% compared to the same period last year[28] - The company's operating revenue for the first half of 2024 was 726.74 million yuan, a year-on-year increase of 3.17%[44] - The company's R&D investment in the first half of 2024 was 164.97 million yuan, a year-on-year increase of 3.29%[44] - The company's software sales revenue was 287.35 million yuan, with a gross profit margin of 62.18%[45] - The company's technical service revenue was 292.69 million yuan, with a gross profit margin of 65.67%[45] - The company's medical software service revenue was 264.76 million yuan, with a gross profit margin of 67.13%[46] - Medical industry revenue increased by 8.61% YoY to 692,741,222.34 RMB, with a gross margin of 54.27%[47] - Software sales revenue grew slightly by 0.02% YoY to 287,346,830.67 RMB, with a gross margin of 62.18%[47] - Technical services revenue rose by 9.00% YoY to 292,692,898.30 RMB, with a gross margin of 65.67%[47] - Medical software services revenue surged by 14.60% YoY to 264,760,707.36 RMB, with a gross margin of 67.13%[47] - Northwest region revenue increased significantly by 76.14% YoY to 85,299,929.89 RMB, with a gross margin of 63.56%[47] - Total operating revenue for the first half of 2024 reached 726,735,755.07 yuan, an increase from 704,387,729.02 yuan in the same period last year[109] - Net profit for the first half of 2024 was 31,659,124.99 yuan, up from 25,653,107.18 yuan in the first half of 2023[110] - R&D expenses increased to 138,166,674.71 yuan in the first half of 2024, compared to 120,996,405.15 yuan in the same period last year[110] - Operating profit for the first half of 2024 was 30,091,181.93 yuan, compared to 20,908,089.16 yuan in the same period last year[110] - Comprehensive income for the first half of 2024 totaled RMB 31,319,447.51, compared to RMB 25,983,946.98 in the same period last year[111] - Net profit attributable to the parent company for the first half of 2024 was RMB 27,036,273.13, up from RMB 24,338,150.24 in the same period last year[111] - Operating income for the first half of 2024 was RMB 594,092,145.56, a slight increase from RMB 577,028,362.28 in the same period last year[112] - R&D expenses for the first half of 2024 increased to RMB 112,581,604.78, up from RMB 107,921,651.77 in the same period last year[112] - Net cash flow from operating activities for the first half of 2024 was RMB 601,541,998.60, slightly down from RMB 605,084,999.23 in the same period last year[114] - Cash received from sales of goods and services for the first half of 2024 was RMB 557,660,669.51, compared to RMB 561,888,724.54 in the same period last year[114] - Cash paid for goods and services for the first half of 2024 was RMB 326,228,627.91, up from RMB 321,840,298.16 in the same period last year[114] - Cash paid to employees for the first half of 2024 increased to RMB 320,765,378.18, compared to RMB 295,281,489.50 in the same period last year[114] - Other comprehensive income after tax for the first half of 2024 was a loss of RMB 339,677.48, compared to a gain of RMB 330,839.80 in the same period last year[113] - Total comprehensive income for the first half of 2024 was a loss of RMB 4,996,020.88, compared to a loss of RMB 3,849,709.33 in the same period last year[113] - Operating cash flow for the first half of 2024 was -192.45 million yuan, a decrease compared to -171.33 million yuan in the same period last year[115] - Investment cash flow for the first half of 2024 was -128.51 million yuan, an improvement from -180.27 million yuan in the same period last year[115] - Financing cash flow for the first half of 2024 was -19.51 million yuan, compared to -42.53 million yuan in the same period last year[115] - Total cash and cash equivalents at the end of the period were 746.96 million yuan, down from 1.08 billion yuan at the end of the same period last year[115] - Parent company's operating cash flow for the first half of 2024 was -150.18 million yuan, compared to -55.26 million yuan in the same period last year[116] - Parent company's investment cash flow for the first half of 2024 was -123.08 million yuan, an improvement from -187.22 million yuan in the same period last year[117] - Parent company's financing cash flow for the first half of 2024 was -17.38 million yuan, compared to -117.20 million yuan in the same period last year[117] - Total cash and cash equivalents of the parent company at the end of the period were 325.90 million yuan, down from 681.72 million yuan at the end of the same period last year[117] - Total owner's equity at the end of the period was 4.66 billion yuan, with minority shareholders' equity accounting for 57.90 million yuan[118] - Comprehensive income for the period was -339,677.48, with a total comprehensive income of 27,375,950.61 and a net comprehensive income of 31,319,447.51[119] - Owner's equity increased by 15,136,461.43 due to owner's investment and capital reduction, primarily from share-based payments[119] - Profit distribution amounted to -15,444,264.92, reflecting the allocation to owners (or shareholders)[119] - The company's total equity at the end of the period was 4,694,895.18, with a minority interest of 62,186,297.72[120] - The initial balance of the period showed total equity of 4,601,787,992.71, with a minority interest of 8,126,624.52[121] - Changes in equity during the period included a decrease of 210,600.00 in share capital and an increase of 30,113,541.65 in capital reserve[121] - Comprehensive income for the period contributed 24,338,150.24 to the total equity, with a minority interest of 1,645,796.74[121] - Share-based payments accounted for 29,743,763.58 of the owner's equity increase[122] - The company's total equity at the end of the period was 4,672,970,316.94, with a minority interest of 39,796,588.65[123] - The company's total owner's equity at the beginning of the period was 4,257,548,105.38 yuan, with a capital reserve of 1,660,979,352.00 yuan and retained earnings of 945,567,359.51 yuan[124] - During the period, the company's comprehensive income totaled -4,996,020.88 yuan, with a decrease in retained earnings of 20,100,608.32 yuan[124] - The company's total owner's equity at the end of the period was 4,252,244,281.01 yuan, with a capital reserve of 1,676,115,813.43 yuan and retained earnings of 925,466,751.19 yuan[125] - The company's total owner's equity at the beginning of the previous period was 4,329,102,036.75 yuan, with a capital reserve of 1,634,031,569.77 yuan and retained earnings of 1,008,283,269.37 yuan[127] - During the previous period, the company's comprehensive income totaled -3,849,709.33 yuan, with a decrease in retained earnings of 19,649,029.37 yuan[127] - The company's total owner's equity at the end of the previous period was 4,340,453,995.87 yuan, with a capital reserve of 1,664,145,111.42 yuan and retained earnings of 988,543,345.04 yuan[128] - The company's registered capital is 1,549,124,692.00 yuan, with a total of 1,549,124,692 shares (1 yuan per share)[129] - The company's main business includes software sales, system integration, and technical services[129] - The company's financial statements are prepared on a going concern basis, with no significant doubts about its ability to continue operations for the next 12 months[130][131] - The company's accounting policies and estimates cover areas such as financial instrument impairment, fixed asset depreciation, and revenue recognition[133] - The company uses RMB as its functional currency[137] - Significant items are defined as those exceeding 0.5% of total assets, including bad debt provisions, prepayments, and capital R&D projects[138] - Subsidiaries and joint ventures are considered significant if their profit or assets exceed 15% of the group's total[139] - The company follows specific accounting methods for both same-control and non-same-control business combinations[140] - Control is determined based on power over investees, variable returns, and ability to influence returns[141] - The company classifies joint arrangements as either joint operations or joint ventures and accounts for them accordingly[142] - Cash equivalents are defined as short-term, highly liquid investments that are readily convertible to known amounts of cash[143] - Foreign currency transactions are translated using the spot exchange rate at the transaction date, with exchange differences recognized in profit or loss[144][145] - Financial assets are classified into three categories at initial recognition: (1) measured at amortized cost, (2) measured at fair value with changes in other comprehensive income, and (3) measured at fair value with changes in current profit or loss[146] - Financial liabilities are classified into four categories at initial recognition: (1) measured at fair value with changes in current profit or loss, (2) financial liabilities from transferred financial assets that do not meet derecognition criteria, (3) financial guarantee contracts and loan commitments not classified as (1), and (4) measured at amortized cost[146] - Financial assets measured at amortized cost are subsequently measured using the effective interest method, with gains or losses recognized in current profit or loss upon derecognition, reclassification, or impairment[146] - Financial assets measured at fair value with changes in other comprehensive income (debt instruments) are subsequently measured at fair value, with interest income, impairment losses, and exchange differences recognized in current profit or loss[146] - Financial assets measured at fair value with changes in current profit or loss are subsequently measured at fair value, with all gains or losses recognized in current profit or loss unless part of a hedging relationship[147] - Financial liabilities measured at fair value with changes in current profit or loss are subsequently measured at fair value, with changes due to the company's own credit risk recognized in other comprehensive income[147] - Financial assets are derecognized when the contractual rights to cash flows expire or when the asset is transferred and meets derecognition criteria under accounting standards[148] - The company uses a three-level hierarchy to determine the fair value of financial instruments, prioritizing observable market data[148] - The company recognizes expected credit losses for financial assets measured at amortized cost, debt instruments measured at fair value with changes in other comprehensive income, and certain other financial instruments[148] - For financial assets with credit impairment, the company recognizes changes in expected credit losses over the entire life of the asset as a loss provision[149] - The expected credit loss rate for commercial acceptance bills within 1 year is 5.00%[151] - The expected credit loss rate for accounts receivable/contract assets within 1 year is 5.00%[151] - The expected credit loss rate for other receivables within 1 year is 5.00%[151] - The expected credit loss rate for commercial acceptance bills between 1-2 years is 20.00%[151] - The expected credit loss rate for accounts receivable/contract assets between 1-2 years is 20.00%[151] - The expected credit loss rate for other receivables between 1-2 years is 20.00%[151] - The expected credit loss rate for commercial acceptance bills between 2-3 years is 30.00%[151] - The expected credit loss rate for accounts receivable/contract assets between 2-3 years is 30.00%[151] - The expected credit loss rate for other receivables between 2-3 years is 30.00%[151] - The expected credit loss rate for commercial acceptance bills between 3-4 years is 50.00%[151] - The company uses the cost method for subsequent measurement of long-term equity investments in subsidiaries and the equity method for investments in associates and joint ventures[156] - For step-by-step disposal of subsidiary investments leading to loss of control, the company assesses whether the transactions constitute a "package deal" based on factors such as transaction terms, consideration, and economic impact[157] - When control over a subsidiary is lost, the remaining equity is remeasured at fair value, and the difference between the consideration received and the share of net assets is recognized in investment income[157] - Investment properties are initially measured at cost and subsequently measured using the cost model, with depreciation or amortization calculated similarly to fixed assets and intangible assets[159] - Fixed assets are depreciated using the straight-line method with varying useful lives: buildings (20-50 years), machinery (3-10 years), vehicles (5-10 years), and other equipment (3-10 years)[161] - Construction in progress is recognized when economic benefits are probable and costs are reliably measurable, and is transferred to fixed assets upon reaching intended use status[162] - Borrowing costs are capitalized when directly attributable to the acquisition, construction, or production of qualifying assets, and capitalization ceases when the asset is ready for use[164] - Intangible assets such as land use rights, software licenses, patents, and franchises are amortized using the straight-line method over their estimated useful lives (5-50 years)[166] - R&D expenses include personnel costs, direct input costs, depreciation, and intangible asset amortization, with allocation based on project hours and usage[167] - Internal R&D project expenditures are classified into research and development phases, with development phase costs capitalized as intangible assets if specific criteria are met[167] - Long-term assets are tested for impairment at each balance sheet date, with impairment losses recognized if the recoverable amount is below the carrying value[169] - Long-term prepaid expenses are amortized over their beneficial period, with any non-beneficial amounts written off immediately[170] - Contract liabilities represent obligations to transfer goods or services to customers for which consideration has been received or is receivable[171] - Short-term employee benefits are recognized as liabilities and expensed during the period the employee provides service[172] - Post-employment benefits are classified into defined contribution and defined benefit plans, with defined benefit obligations measured using actuarial assumptions[173] - Termination benefits are recognized when the company can no longer unilaterally withdraw the offer or when restructuring costs are recognized[174] - Other long-term employee benefits are treated similarly to defined benefit plans, with costs recognized in the period incurred[175] - Provisions are recognized for obligations arising from guarantees, litigation, product warranties, and onerous contracts, measured at the best estimate of the expenditure required[176] - The company recognizes revenue for software sales at a point in time when the company completes its performance obligations and the customer confirms acceptance, payment is received, or the right to receive payment is established, and related economic benefits are likely to flow in[180][181] - Technical services, including software development and hardware/software maintenance, are recognized as revenue at a point in time for software development and over time for maintenance services based on the progress of the service period[180][181] - System integration services, including computer information equipment system integration and intelligent network cabling engineering integration, are recognized as revenue at a point in time for equipment integration and over time for cabling projects based on the actual progress of the project[180][181] - The company assesses contracts at the start date to identify individual performance obligations and determine whether they are satisfied over time or at a point in time[179] - Revenue is measured based on the transaction price allocated to each performance obligation, excluding amounts collected on behalf of third parties or expected to be refunded to customers[179] - For contracts with variable consideration, the company estimates the transaction price using the expected value or most likely amount, ensuring it does not exceed the amount that is highly probable of not reversing[179] - Contracts with significant

到目前的一个大家的一个对于我们在目前的一个经营状况的一个大致的分享另外呢我也想跟大家再继续更新一下因为前期也能看到对于电子定位的一些评级的一些变化包括它标准的这样的一些变化和名称的变化包括它可能设计的一些范围有相相相应的一些增加可能设计了原来就不太去在整个评级过程当中也增加了相应的这种范围比如说它的一个互联互通啊然后一些 就是新一创的要求国产化的适配也包括了相应的一些人工智能的一些方面的增加所以这个呢其实会在我们接下来对于医疗机构的就是电子病例评级当中会去将原来可能会涉及这些新进化建设当中的可选项变成了必选项 所以在我们接下来的信息化建设过程当中对于已经在排队做电子病例评级的他可能接下来就是部立的专家下来做相应的这个电子病例评级的时候他的侧重点他的观察点可能会向这个新的标准当中去做相应的设计那这个会在我们接下来对于院站的新化建设当中去做及时的补充和完善但是对于我们现在目前大家所关心的就是说是否因为这些 刘仲敬 明年的整个院端的电子病历的这种需求上来看或者说它针对于这些新的标准的变化它去逐渐完善更多的一些新型化建设的需求上来看它可能会有适量的增加但是量级我们觉得应该也不会是特别大会有适当的变化因为跟大家在分享交 ...